Accurate and easy-to-use tool to help determine vaccination status of patient’s vaccinated against Pneumococcal diseases.
Logan, UT, August 25th 2021 – Quansys Biosciences announces a new tool to aid health care providers and researchers in the fight against invasive pneumococcal diseases. Streptococcus pneumoniae is the most common bacterial cause of pneumonia in the world. The bacterium is also capable of causing deadly meningitis and bacteremia, with young children and the elderly being the most vulnerable. The CDC recommends that children younger than 2 and adults over 65 become vaccinated to prevent complications.
The new Q-Plex™ Human Pneumococcal IgG (23-Plex) measure’s an individual’s ability to produce antibodies towards 23 common disease-causing serotypes of S. pneumonia targeted by the Pneumovax®23 (Merck & Co., Kenilworth, NJ). Measuring antibody levels allows health care providers to determine vaccination status and researchers to measure responses to different available vaccines. The assay is designed with traditional ELISA methodology in mind, making it easy to use and a cost-effective solution. The assay utilizes a two-plate system to measure antibody responses against the 23 targeted serotypes and is available individually as the Q-Plex™ Human Pneumococcal IgG (14-Plex) and Q-Plex™ Human Pneumococcal IgG (9-Plex) to best suit the needs of different projects.
About Quansys Biosciences
Quansys Biosciences is dedicated to the development and manufacture of multiplexed assays for protein quantification. Quansys Biosciences Q-Plex Array Technology aids researchers in better understanding of disease. The Q-Plex Technology includes multiplex and singleplex assays built to maximize the quantity and quality of data from biological samples. To support its multiplex assays, Quansys also provides the Q-View Imager system consisting of: Q-View Software, a user-friendly software package that enables the acquisition and analysis of large amounts of multiplex data, and the Q-View Imager, a high-resolution imaging system used to capture chemiluminescent assays. Quansys Biosciences was founded in 2005 as a Spendlove Research Foundation company.